Full Text Journal Articles by
Author Marcus Neubauer

Advertisement

Find full text journal articles






The Centers for Medicare & Medicaid Services Oncology Care Model Halfway Through - Perspectives from Diverse Participants.

Ronald M Kline, Michelle Brown, Nikolas Buescher, John Cox, Elizabeth Horenkamp, Russell Hoverman, Marcus Neubauer, Randall Oyer, Anne Marie Fraley Rainey, Larisa Strawbridge,

The Oncology Care Model (OCM) is a 5-year model developed and tested by the Centers for Medicare & Medicaid Services that uses an episode-based payment model triggered by the receipt of chemotherapy to test if changing payment mechanisms, in conjunction with a requirement for enhanced patient services, can generate clinical ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Redefining Quality Measurement in Cancer Care.

Elizabeth A Nardi, James McCanney, Katy Winckworth-Prejsnar, Alyssa A Schatz, Kerin Adelson, Marcus Neubauer, Mary Lou Smith, Ronald Walters, Robert W Carlson,

Quality measurement in oncology is increasing in significance as payment schemes shift from volume to value. As demand for quality measures increases, challenges in the development of quality measures, standardization across measures, and the limitations of health information technology have become apparent. Moreover, the time and financial burden associated with ... Read more >>

J Natl Compr Canc Netw (Journal of the National Comprehensive Cancer Network : JNCCN)
[2018, 16(5):473-478]

Cited: 1 time

View full text PDF listing >>



Advertisement

Three-Year Results of a Medicare Advantage Cancer Management Program.

J Russell Hoverman, Marcus A Neubauer, Melissa Jameson, Jad E Hayes, Kathryn J Eagye, Mitra Abdullahpour, Wendy J Haydon, Maria Sipala, Amy Supraner, Michael A Kolodziej, Diana K Verrilli,

PURPOSE:Reform of cancer care delivery seeks to control costs while improving quality. Texas Oncology collaborated with Aetna to conduct a payer-sponsored program that used evidence-based treatment pathways, a disease management call center, and an introduction to advance care planning to improve patient care and reduce total costs. METHODS:From June 1, ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2018, 14(4):e229-e237]

Cited: 0 times

View full text PDF listing >>



Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.

Cynthia Osborne, Jagathi D Challagalla, Charles F Eisenbeis, Frankie Ann Holmes, Marcus A Neubauer, Nicholas W Koutrelakos, Carlos A Taboada, Sasha J Vukelja, Sharon T Wilks, Mary Ann Allison, Praveen Reddy, Scot Sedlacek, Yunfei Wang, Lina Asmar, Joyce O'Shaughnessy,

BACKGROUND:Hormonal therapies and single-agent sequential chemotherapeutic regimens are the standards of care for HER2- metastatic breast cancer (MBC). However, treating patients with hormone-refractory and triple negative (TN) MBC remains challenging. We report the results of combined ixabepilone and carboplatin in a single-arm phase II trial. PATIENTS AND METHODS:In the present ... Read more >>

Clin. Breast Cancer (Clinical breast cancer)
[2018, 18(1):e89-e95]

Cited: 0 times

View full text PDF listing >>



Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.

Michael V Seiden, Marcus Neubauer, Diana Verrilli,

Am J Manag Care (The American journal of managed care)
[2017, 23(2 Spec No.):SP69-SP77]

Cited: 0 times

View full text PDF listing >>



Improving incidence of code status documentation through process and discipline.

Marcus A Neubauer, Cynthia B Taniguchi, J Russell Hoverman,

Documentation of a patient's preferred code status is a critical outcome of advance care planning. Although there is agreement that code status is valuable information, little progress has been made to increase the incidence of documented code status within the medical record in an outpatient setting. Incidence of code status ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2015, 11(2):e263-6]

Cited: 8 times

View full text PDF listing >>



Expectations in the care of lung cancer.

Rogerio Lilenbaum, Natasha B Leighl, Marcus Neubauer,

One of the main challenges oncologists face in the care of patients with lung cancer is the decision to incorporate new clinical trial data into routine clinical practice. Beyond the question of statistical significance, which is a more objective metric, are the results meaningful and applicable to a broader population? ... Read more >>

Am Soc Clin Oncol Educ Book (American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting)
[2015, :e420-4]

Cited: 0 times

View full text PDF listing >>



Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

Joyce O'Shaughnessy, Lee Schwartzberg, Michael A Danso, Kathy D Miller, Hope S Rugo, Marcus Neubauer, Nicholas Robert, Beth Hellerstedt, Mansoor Saleh, Paul Richards, Jennifer M Specht, Denise A Yardley, Robert W Carlson, Richard S Finn, Eric Charpentier, Ignacio Garcia-Ribas, Eric P Winer,

PURPOSE: There is a lack of treatments providing survival benefit for patients with metastatic triple-negative breast cancer (mTNBC), with no standard of care. A randomized phase II trial showed significant benefit for gemcitabine, carboplatin, and iniparib (GCI) over gemcitabine and carboplatin (GC) in clinical benefit rate, response rate, progression-free survival ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2014, 32(34):3840-3847]

Cited: 94 times

View full text PDF listing >>



Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Edward S Kim, Marcus Neubauer, Allen Cohn, Lee Schwartzberg, Lawrence Garbo, John Caton, Francisco Robert, Craig Reynolds, Terry Katz, Sreeni Chittoor, Lorinda Simms, Scott Saxman,

BACKGROUND: Available preclinical and phase 2 clinical data suggest that the addition of cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), to chemotherapy might improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to assess whether the addition of cetuximab to chemotherapy improved ... Read more >>

Lancet Oncol. (The Lancet. Oncology)
[2013, 14(13):1326-1336]

Cited: 38 times

View full text PDF listing >>



Opening the black box: the impact of an oncology management program consisting of level I pathways and an outbound nurse call system.

J Russell Hoverman, Ira Klein, Debra W Harrison, Jad E Hayes, Jody S Garey, Robyn Harrell, Maria Sipala, Scott Houldin, Melissa D Jameson, Mitra Abdullahpour, Jessica McQueen, Greg Nelson, Diana K Verrilli, Marcus Neubauer,

The Innovent Oncology Program aims to improve the value of cancer care delivered to patients. McKesson Specialty Health and Texas Oncology (TXO) collaborated with Aetna to launch a pilot program. The study objectives were to evaluate the impact of Innovent on Level I Pathway compliance, implement the Patient Support Services ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2014, 10(1):63-67]

Cited: 21 times

View full text PDF listing >>



Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

Samir E Witta, Robert M Jotte, Katrik Konduri, Marcus A Neubauer, Alexander I Spira, Robert L Ruxer, Marileila Varella-Garcia, Paul A Bunn, Fred R Hirsch,

Histone deacetylase inhibitors (HDACis) have been shown to overcome resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) linked to epigenetic changes and epithelial-mesenchymal transition (EMT) state. This randomized phase II study evaluated the outcome of erlotinib with and without the isoform selective HDACi, entinostat.Previously treated patients with stage ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2012, 30(18):2248-2255]

Cited: 87 times

View full text PDF listing >>



A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

Alexander I Spira, Nicholas O Iannotti, Michael A Savin, Marcus Neubauer, Nashat Y Gabrail, Ronald H Yanagihara, Edith A Zang, Patricia E Cole, Dale Shuster, Asha Das,

This open-label phase II study assessed the efficacy and tolerability of eribulin, a non-taxane microtubule dynamics inhibitor with novel mechanism of action, as monotherapy in patients who have advanced non-small-cell lung cancer (NSCLC).Enrolled patients had progressed during or after platinum-based doublet chemotherapy. Initially, two patient cohorts (taxane-pre-treated and taxane-naïve) received ... Read more >>

Clin Lung Cancer (Clinical lung cancer)
[2012, 13(1):31-38]

Cited: 14 times

View full text PDF listing >>



Benchmarks for value in cancer care: an analysis of a large commercial population.

Michael Kolodziej, J Russell Hoverman, Jody S Garey, Janet Espirito, Sheetal Sheth, Aimee Ginsburg, Marcus A Neubauer, Debra Patt, Barry Brooks, Charles White, Mark Sitarik, Roger Anderson, Roy Beveridge,

Cancer costs are increasing at an unprecedented rate. Key cost drivers include chemotherapy, hospital admissions/emergency room visits, and aggressive end-of-life care. We sought to evaluate these costs in a commercial payer population in collaboration with consultants from Milliman.We used a retrospective analysis of Medstat 2007 to evaluate chemotherapy costs and ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2011, 7(5):301-306]

Cited: 23 times

View full text PDF listing >>



Creating a process to standardize regimen order sets within an electronic health record.

Leslie T Busby, Sheetal Sheth, Jody Garey, Aimee Ginsburg, Thomas Flynn, Michael A Willen, Scott Kruger, Marcus A Neubauer, Michael Kolodziej, David Chang, Eric Scott Palmer, Margaret McGuinness, Nancy J Egerton, Jan Merriman, Eileen B Herbeck, Alison Fetter, Linda Frisk, Mark Sitarik, Roger Anderson, Roy Beveridge,

PURPOSE:US Oncology uses regimen order sets in clinical practice to treat patients. However, the process to assure accuracy and upkeep of these order sets has not been described. The purpose of this project was to evaluate the regimens housed in the electronic health record, iKnowMed, to determine their appropriateness and ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2011, 7(4):e8-e14]

Cited: 3 times

View full text PDF listing >>



An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

Allen L Cohn, Grace C Shumaker, Pankaj Khandelwal, David A Smith, Marcus A Neubauer, Nilesh Mehta, Donald Richards, David L Watkins, Kathy Zhang, Mohamed R Yassine,

This prospective analysis evaluated the effect of tumor KRAS status on efficacy of second-line panitumumab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI).This phase 2, open-label, single-arm study enrolled patients with unresectable, measurable metastatic colorectal cancer (mCRC) after failure of first-line treatment with oxaliplatin-based chemotherapy plus bevacizumab. Patients received panitumumab 6 mg/kg plus FOLFIRI ... Read more >>

Clin Colorectal Cancer (Clinical colorectal cancer)
[2011, 10(3):171-177]

Cited: 24 times

View full text PDF listing >>



Pathways, outcomes, and costs in colon cancer: retrospective evaluations in 2 distinct databases.

J Russell Hoverman, Thomas H Cartwright, Debra A Patt, Janet L Espirito, Matthew P Clayton, Jody S Garey, Terrance J Kopp, Michael Kolodziej, Marcus A Neubauer, Kathryn Fitch, Bruce Pyenson, Roy A Beveridge,

OBJECTIVE: The goal of this study was to use 2 separate databases to evaluate the clinical outcomes and the economic impact of adherence to Level I Pathways, an evidence-based oncology treatment program in the treatment of colon cancer. PATIENTS AND METHODS: The first study used clinical records from an electronic ... Read more >>

Am J Manag Care (The American journal of managed care)
[2011, 17 Suppl 5 Developing:SP45-52]

Cited: 6 times

View full text PDF listing >>



Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases.

J Russell Hoverman, Thomas H Cartwright, Debra A Patt, Janet L Espirito, Matthew P Clayton, Jody S Garey, Terrance J Kopp, Michael Kolodziej, Marcus A Neubauer, Kathryn Fitch, Bruce Pyenson, Roy A Beveridge,

The goal of this study was to use two separate databases to evaluate the clinical outcomes and the economic impact of adherence to Level I Pathways, an evidence-based oncology treatment program in the treatment of colon cancer.The first study used clinical records from an electronic health record (EHR) database to ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2011, 7(3 Suppl):52s-9s]

Cited: 34 times

View full text PDF listing >>



A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.

Charles H Weissman, Craig H Reynolds, Marcus A Neubauer, Sharon Pritchard, Svetlana Kobina, Lina Asmar,

PURPOSE: This phase III study compared the efficacy and tolerability of gemcitabine and oxaliplatin (GEMOX) with paclitaxel and carboplatin (PCb) in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer. PATIENTS AND METHODS: Patients aged 18 years or older were randomized to PCb (paclitaxel 225 mg/m followed by carboplatin area ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2011, 6(2):358-364]

Cited: 14 times

View full text PDF listing >>



Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

Matthew D Galsky, Daniel D Von Hoff, Marcus Neubauer, Thomas Anderson, Mark Fleming, Yasir Nagarwala, Janine M Mahoney, Dawn Midwinter, Linda Vocila, Tal Z Zaks,

BACKGROUND: To explore the activity of lapatinib with a novel trial design focused on the drug target rather than on histology. METHODS: Patients with HER2 amplified gastro-esophageal, bladder, ovarian, or uterine tumors were enrolled into a double-blinded randomized discontinuation study of lapatinib 1,500 mg PO daily. The planned sample size ... Read more >>

Invest New Drugs (Investigational new drugs)
[2012, 30(2):695-701]

Cited: 28 times

View full text PDF listing >>



A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.

John Pippen, Anthony D Elias, Marcus Neubauer, Christopher Stokoe, LaTrice G Vaughn, Yanping Wang, Mauro Orlando, Oluwatoyin Shonukan, Joseph Muscato, Joyce A O'Shaughnessy, Julie Gralow,

PURPOSE: This phase II trial assessed efficacy and safety of pemetrexed plus gemcitabine to treat metastatic or locally advanced breast cancer in patients previously treated with taxanes. PATIENTS AND METHODS: Eligible women with advanced breast cancer treated with taxanes in the adjuvant or metastatic setting received pemetrexed 500 mg/m2 on ... Read more >>

Clin. Breast Cancer (Clinical breast cancer)
[2010, 10(2):148-153]

Cited: 6 times

View full text PDF listing >>



Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting.

Marcus A Neubauer, J Russell Hoverman, Michael Kolodziej, Lonny Reisman, Stephen K Gruschkus, Susan Hoang, Albert A Alva, Marilyn McArthur, Michael Forsyth, Todd Rothermel, Roy A Beveridge,

The goal of this study was to evaluate the cost-effectiveness of Level I Pathways, a program designed to ensure the delivery of evidence-based care, among patients with non-small-cell lung cancer (NSCLC) treated in the outpatient community setting.We included patients with NSCLC initiating a chemotherapy regimen between July 1, 2006, and ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2010, 6(1):12-18]

Cited: 72 times

View full text PDF listing >>



Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.

J Randolph Hecht, Edith Mitchell, Marcus A Neubauer, Howard A Burris, Paul Swanson, Timothy Lopez, Glenn Buchanan, Maureen Reiner, Jennifer Gansert, Jordan Berlin,

Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is approved as monotherapy for the treatment of metastatic colorectal cancer. We evaluated the association of tumor EGFR expression levels with outcomes in patients with chemorefractory metastatic colorectal cancer.Two phase II, multicenter, single-arm, open-label studies enrolled chemorefractory patients with ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2010, 16(7):2205-2213]

Cited: 44 times

View full text PDF listing >>



Commentary: do guidelines influence physician practice behavior? The experience with erythropoiesis-stimulating agents.

Marcus Neubauer, Roy A Beveridge, Michael Kolodziej,

J Oncol Pract (Journal of oncology practice)
[2009, 5(5):243-244]

Cited: 0 times

View full text PDF listing >>



Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Nasser Hanna, Marcus Neubauer, Constantin Yiannoutsos, Ronald McGarry, James Arseneau, Rafat Ansari, Craig Reynolds, Ramaswamy Govindan, Anton Melnyk, William Fisher, Donald Richards, Daniel Bruetman, Thomas Anderson, Naveed Chowhan, Sreenivasa Nattam, Prasad Mantravadi, Cynthia Johnson, Tim Breen, Angela White, Lawrence Einhorn, , ,

PURPOSE: Concurrent chemoradiotherapy is standard treatment for patients with inoperable stage III non-small-cell lung cancer (NSCLC). A phase II study by the Southwest Oncology Group using consolidation docetaxel after cisplatin (P), etoposide (E), and radiation (XRT) resulted in a median survival time (MST) of 26 months. This randomized phase III ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2008, 26(35):5755-5760]

Cited: 180 times

View full text PDF listing >>



Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.

Mark A Socinski, Robert N Raju, Marcus Neubauer, David A Smith, Donald A Richards, Michael Savin, Robert L Ruxer, Craig H Reynolds, Feng Zhan, Jane L Bromund, Ruqin Chen, Coleman Obasaju,

INTRODUCTION: We undertook a phase II trial to assess the efficacy and safety of single-agent pemetrexed (P) in relapsed small-cell lung cancer (SCLC) patients. METHODS: Patients had limited- or extensive-stage SCLC, performance status 0 to 2, and one prior chemotherapy regimen. Initial P dose was 500 mg/m every 21 days. ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2008, 3(11):1308-1316]

Cited: 11 times

View full text PDF listing >>



Advertisement

Disclaimer
25.0275 s